Kathy Hopinkah Hannan - Jun 11, 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Director
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Jun 11, 2025
Transactions value $
$0
Form type
4
Date filed
6/13/2025, 04:19 PM
Previous filing
May 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hannan Kathy Hopinkah Director C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, BOSTON /s/ Karen Tepichin, Attorney-in-Fact 2025-06-13 0001767813

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +10.8K +258.84% 15K Jun 11, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -10.8K -100% 0 Jun 11, 2025 Class A Common Stock 10.8K $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Kathy Hopinkah Hannan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 13, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.